Your Guide to Financial Freedom
The artificial intelligence sector experienced a volatile trading session on Wednesday as investors aggressively purchased the dip in major memory chip stocks. Shares of Micron Technology (MU), SanDisk (SNDK), and Western Digital (WDC) all managed to trim earlier losses throughout the day, signaling a potential stabilization in market sentiment for hardware providers. Understanding the Market … Read more
Intuitive Machines, Inc. (NASDAQ:LUNR) is capturing significant investor attention. Following key NASA lunar lander awards, prominent financial firms like Craig Hallum and B. Riley have reiterated strong “Buy” ratings for the space exploration company. On July 1, Craig Hallum analyzed NASA’s latest Commercial Lunar Payload Services (CLPS) program awards, confirming they largely met market expectations. … Read more
Argus Research, in its report dated July 09, 2026, highlights The AES Corporation (AES) as a stock exhibiting a “high yield for a while.” With AES currently trading at $14.84 per share, this assessment warrants a closer examination of the company’s operational backbone and its position within the dynamic Utilities sector. Understanding the nuances of … Read more
Redwire Corporation (NYSE:RDW), a notable player among under-the-radar stocks, recently announced two significant contract wins. These agreements underscore the company’s expanding influence across critical sectors: national security and advanced space technology. Strengthening Maritime Security with Advanced UAS Technology On June 30, Redwire Corporation finalized a pivotal contract to supply its advanced Penguin Mk2.5 VTOL Uncrewed … Read more
Freedom Capital Initiates Coverage on Tempus AI (TEM) Freedom Capital has officially begun coverage of Tempus AI, Inc. (NASDAQ:TEM) with a ‘Hold’ rating, assigning a price target of $59 on July 1. This move positions Tempus AI, a prominent player in the rapidly expanding healthcare AI sector, under closer scrutiny from institutional investors. The firm’s … Read more
Pagaya Technologies Ltd. (NASDAQ:PGY), a significant player in the burgeoning financial technology sector, has recently garnered substantial attention from financial analysts. On June 11, Texas Capital initiated coverage of the firm with a prominent ‘Buy’ rating, setting an optimistic price target of $27 per share. This endorsement highlights Pagaya’s position as one of the standout … Read more
Exelixis (EXEL) Oncology Pipeline: A Closer Look at Clinical Performance Exelixis, Inc. (NASDAQ:EXEL), a prominent oncology biopharmaceutical company, navigates a complex landscape of drug development and regulatory milestones. The company’s recent disclosure on June 22 regarding its Phase 3 STELLAR 303 data has garnered investor attention, offering insights into its therapeutic candidates for metastatic colorectal … Read more
Bank of America (BofA) has adjusted its price target for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), reducing it from $550 to $542. The firm has, however, maintained a Neutral rating on the biopharmaceutical company’s stock, signaling a cautious but not overtly pessimistic outlook. This revision primarily stems from an evolving perception of the market for Rezdiffra, Madrigal’s … Read more
IREN Limited (NASDAQ:IREN), recognized as a promising, often overlooked stock, has made headlines with a substantial executive compensation announcement. On July 2, Forbes reported that the company’s board sanctioned a four-year equity package valued at an impressive US$788 million for its co-founders and co-CEOs, Will Roberts and Daniel Roberts. This significant payout comprises over 9 … Read more
Axsome Therapeutics (AXSM) Emerges as ‘Under-the-Radar’ Investment Leader Axsome Therapeutics, Inc. (NASDAQ:AXSM), a commercial-stage biopharmaceutical company, has recently captured significant market attention, cementing its position as one of the standout “under-the-radar” stocks for astute investors. The company specializes in developing innovative therapies tailored for managing central nervous system (CNS) disorders, a field with substantial unmet … Read more